Variation in the α2A-adrenergic receptor gene and risk of gestational diabetes

Pharmacogenomics. 2017 Oct;18(15):1381-1386. doi: 10.2217/pgs-2017-0079. Epub 2017 Oct 4.

Abstract

Aim: Sympathetic activation suppresses insulin secretion via pancreatic ADRA2A. Because sympathetic activity and insulin demand increase during pregnancy, we tested the hypothesis that ADRA2A variants are associated with gestational diabetes (GDM).

Patients & methods: Among Caucasian pregnant women without pre-existing diabetes, we genotyped 458 who had GDM and 1537 without GDM for seven ADRA2A variants.

Results: rs1800038 (OR: 2.34; p = 0.020) and rs3750625 (OR: 1.56; p = 0.010) increased the risk of GDM, and rs11195418 decreased it (OR: 0.62; p = 0.025). The associations remained significant after adjustment for maternal age, maternal BMI, parity and a genetic risk score that included variants previously associated with Type 2 diabetes mellitus and GDM.

Conclusion: ADRA2A genetic variation contributes independently to the risk of GDM in Caucasian women.

Keywords: ADRA2A variants; Caucasians; gestational diabetes.

MeSH terms

  • Adult
  • Alleles
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes, Gestational / genetics*
  • Female
  • Genetic Predisposition to Disease / genetics*
  • Genetic Variation / genetics*
  • Genotype
  • Humans
  • Insulin / genetics
  • Pregnancy
  • Receptors, Adrenergic, alpha-2 / genetics*
  • Risk Factors
  • White People / genetics

Substances

  • ADRA2A protein, human
  • Insulin
  • Receptors, Adrenergic, alpha-2